@entity7375 associated with XXXX : an 11-year follow-up.

@entity1 @entity10244 @entity267 @entity7375 @entity989 @entity231 @entity1529 @entity1530 @entity4182 @entity1103 @entity1694 @entity3067 @entity194 @entity941 @entity3 @entity56 @entity320 @entity3171 @entity1533
PURPOSE: To report a case of @entity7375 associated with cutaneous @entity320 (MM) and non-pigmented nodular @entity3 after a 10-year recurrence-free interval. METHODS: Case report with long-term follow-up of 11 years. Ocular examinations included best-corrected visual acuity (ETDRS charts), fundus photography, @entity941 angiography, and computer-assisted perimetry. In addition, human leukocyte antigen (HLA) typing was performed. RESULTS: A 48-year-old white female @entity1 developed @entity7375 5 years after she had undergone surgical treatment of a superficial spreading @entity320 on her back in 1991. The first symptoms were @entity3067 followed by growth of non-pigmented hair after 8 months. In our clinic, she presented 18 months later with cells and opacification in the vitreous, a macular and @entity3171 and @entity194 of the @entity989 ( @entity989 ). The anterior segment showed endothelial precipitates of the @entity267 , and a progressive secondary @entity231 . Fluorescein angiography detected a bilateral @entity1103 and the optic disc, and focal leakage in the @entity989 level. During follow-up the @entity1 developed more cutaneous signs, such as @entity1694 and @entity10244 . A non-pigmented lymph node MM @entity3 was diagnosed after a 10-year disease-free interval. HLA typing was positive for @entity1529 *01, @entity1529 *24, @entity1530 *08, @entity1530 *39, @entity1533 *03, and @entity1533 *11. CONCLUSION: Our findings suggest that the described ocular findings of @entity7375 may represent a component of a syndrome consisting also of @entity320 -associated @entity4182 . Within the framework of current concepts of immunity in @entity1 with MM and VKH, the long recurrence-free interval might support the hypothesis of an autoimmune or @entity56 process against melanocytes. The use of immunosuppressive therapy in the treatment of VKH and its potential influence on the development of @entity3 should be carefully reconsidered.
